Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- ADVISEIndependent statistical analysis of A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Advisor HD Grid Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Advisor HD Grid Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03733392).
- AEGiSIndependent statistical analysis of Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Afatinib in Subjects With Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Afatinib in Subjects With Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02096718).
- AFCAREIndependent statistical analysis of Feasibility Study to Improve AF Outcomes Using a Digital Application for CV Risk Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- AFEQTIndependent statistical analysis of Colorectal Cancer Metastatic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670721).
- AFFILIATEIndependent statistical analysis of Effects of Oral Sildenafil on Mortality in Adults With PAH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02060487).
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Aflibercept for Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Aflibercept for Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00437034).
- AGATE-1Independent statistical analysis of A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and…
- AGAVE-201Independent statistical analysis of A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage: Complete Statistical AnalysisIndependent statistical analysis of Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01530880).
- AGN-199201 for the Treatment of Erythema With Rosacea: Complete Statistical AnalysisIndependent statistical analysis of AGN-199201 for the Treatment of Erythema With Rosacea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01735201).
- AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AGREEIndependent statistical analysis of MPC-004 for the Treatment of an Acute Gout Flare: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00506883).
- AHIndependent statistical analysis of A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- AHAvsSIMIndependent statistical analysis of A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT): primary endpoint results, effect estimate with confidence interval, sample-size…
- AHEADIndependent statistical analysis of Cardiovalve Transfemoral Mitral Valve System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03813524).
- AIDAIndependent statistical analysis of Adjusting Insulin Delivery to Activity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02299479).
- Air-Q® SP Versus Air-Q® and I-gel: A Randomized Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Air-Q® SP Versus Air-Q® and I-gel: A Randomized Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01592760).
- AIRSIndependent statistical analysis of A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01535118).
- Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath: Complete Statistical AnalysisIndependent statistical analysis of Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness…
- AIVARIXIndependent statistical analysis of Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ALDERIndependent statistical analysis of Anxiety Lowering and Deprescribing Through Emotion Regulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06359314).
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01226420).
- Alemtuzumab + Rituximab Consolidation in CLL: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab + Rituximab Consolidation in CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00771602).
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361711).
- Algorithm for Predicting the Unfavorable Course of Sepsis in Children: Complete Statistical AnalysisIndependent statistical analysis of Algorithm for Predicting the Unfavorable Course of Sepsis in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05908162).
- ALIGN: Aligning Medications With What Matters Most (Demonstration): Complete Statistical AnalysisIndependent statistical analysis of ALIGN: Aligning Medications With What Matters Most (Demonstration): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06335953).
- Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: primary endpoint…
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Alkali Therapy in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Alkali Therapy in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01452412).
- Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ALLIndependent statistical analysis of Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ALLEGRO-2b/3Independent statistical analysis of PF-06651600 for the Treatment of Alopecia Areata: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03732807).
- Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: Complete Statistical AnalysisIndependent statistical analysis of Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs: primary endpoint results, effect estimate with confidence interval, sample-size…
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Stem Cell Transplant for CLL: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant for CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01629511).
- AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: Complete Statistical AnalysisIndependent statistical analysis of AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides: Complete Statistical AnalysisIndependent statistical analysis of Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…